Who is sponsoring NCT00005948?

NCT00005948 is sponsored by Fred Hutchinson Cancer Center.

What drugs are being tested in NCT00005948?

Interventions: aldesleukin, recombinant interferon alfa, sargramostim, busulfan, peripheral blood stem cell transplantation.

What is the status of NCT00005948?

NCT00005948 is currently COMPLETED.

Last reviewed 2010-03-31 · How we verify

A Pilot Study of High Dose Busulfan Combined With IL2/GM-CSF Activated Autologous/Syngeneic PBSC, Sequential IL2/GM-CSF Therapy and Alpha Interferon Maintenance Therapy as Treatment of CML

NCT00005948 Phase 2 COMPLETED

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. PURPOSE: Phase II trial to study the effectiveness of chemotherapy followed by peripheral stem cell transplantation and biological therapy in treating patients who have chronic myelogenous leukemia.

Details

Lead sponsor	Fred Hutchinson Cancer Center
Phase	Phase 2
Status	COMPLETED
Start date	2000-01
Completion	2001-10

Conditions

Leukemia

Interventions

aldesleukin
recombinant interferon alfa
sargramostim
busulfan
peripheral blood stem cell transplantation

Countries

United States